Motoi Hosoe

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.

H. Kerstjens, C. Gessner, R. V. van Zyl-Smit, 2021, Respiratory medicine.

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies

H. Kerstjens, Y. Gon, K. Chapman, 2021, BMJ Open Respiratory Research.

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

H. Sagara, Y. Gon, M. Hosoe, 2021, BMJ Open Respiratory Research.

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study

L. Hang, S. H. Lee, Y. Fukuchi, 2012, Respirology.

Efficacy,Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease

R. Woessner, Soichiro Matsushima, B. Kramer, 2011, Clinical drug investigation.

Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.

H. Makita, Y. Fukuchi, B. Kramer, 2010, Allergology international : official journal of the Japanese Society of Allergology.

Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.

K. Kostikas, R. V. van Zyl-Smit, J. Maspero, 2023, Respiratory medicine.

24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.

M. Adachi, M. Ichinose, B. Kramer, 2010, Respiratory medicine.

Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies

H. Sagara, M. Hosoe, A. Pethe, 2022, The Journal of asthma : official journal of the Association for the Care of Asthma.